Immunocore Holdings (IMCR) Aandelenoverzicht
Immunocore Holdings plc houdt zich, samen met haar dochterondernemingen, bezig met de ontwikkeling en commercialisering van immunomodulerende geneesmiddelen voor patiënten met kanker, infectieziekten en auto-immuunziekten in de Verenigde Staten, Europa en internationaal. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 4/6 |
| Toekomstige groei | 4/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 4/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
Geen risico's gedetecteerd voor IMCR uit onze risicocontroles.
IMCR Community Fair Values
Create NarrativeSee what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Immunocore Holdings plc Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$32.60 |
| 52 Week Hoogtepunt | US$40.71 |
| 52 Week Laag | US$27.56 |
| Bèta | 0.74 |
| 1 maand verandering | -4.68% |
| 3 maanden verandering | 12.57% |
| 1 Jaar Verandering | -7.49% |
| 3 jaar verandering | -38.25% |
| 5 jaar verandering | -4.90% |
| Verandering sinds IPO | -24.54% |
Recent nieuws en updates
Narratiefupdate • Aug 21
IMCR: Phase III Melanoma Readouts Will Drive 2026 Capital Producer Transition
Analysts have trimmed their fair value estimate for Immunocore Holdings from about $66.57 to $62.50, citing updated assumptions that include slightly higher discount rates, more moderate revenue growth, stronger profit margins and a lower future P/E multiple, as well as recent Street targets of $50 and $43 that reflect confidence in the Kimmtrak franchise and upcoming Phase III readouts. Analyst Commentary on Immunocore Holdings Recent Street research on Immunocore Holdings centers on how durable the Kimmtrak revenue base can be and what upcoming clinical readouts might mean for long term growth and valuation.
Narratiefupdate • Jun 25
IMCR: Future Upside Will Rely On Melanoma Pipeline Trial Progress
Analysts maintained their $34.00 price target on Immunocore Holdings, citing only minor adjustments to assumptions for the discount rate, revenue growth and profit margins that did not materially change their overall view on the stock. What’s in the News for Immunocore Holdings Immunocore Holdings reported updated Phase 1/2 data for brenetafusp in heavily pretreated advanced melanoma, with brenetafusp monotherapy showing a 6‑month overall survival rate of 87% and a disease control rate of 52% in HLA‑A*02:01‑positive patients, according to presentations at the 2026 American Society of Clinical Oncology Annual Meeting.Recent updates
Narratiefupdate • Aug 21
IMCR: Phase III Melanoma Readouts Will Drive 2026 Capital Producer Transition
Analysts have trimmed their fair value estimate for Immunocore Holdings from about $66.57 to $62.50, citing updated assumptions that include slightly higher discount rates, more moderate revenue growth, stronger profit margins and a lower future P/E multiple, as well as recent Street targets of $50 and $43 that reflect confidence in the Kimmtrak franchise and upcoming Phase III readouts. Analyst Commentary on Immunocore Holdings Recent Street research on Immunocore Holdings centers on how durable the Kimmtrak revenue base can be and what upcoming clinical readouts might mean for long term growth and valuation.Narratiefupdate • Jun 25
IMCR: Future Upside Will Rely On Melanoma Pipeline Trial Progress
Analysts maintained their $34.00 price target on Immunocore Holdings, citing only minor adjustments to assumptions for the discount rate, revenue growth and profit margins that did not materially change their overall view on the stock. What’s in the News for Immunocore Holdings Immunocore Holdings reported updated Phase 1/2 data for brenetafusp in heavily pretreated advanced melanoma, with brenetafusp monotherapy showing a 6‑month overall survival rate of 87% and a disease control rate of 52% in HLA‑A*02:01‑positive patients, according to presentations at the 2026 American Society of Clinical Oncology Annual Meeting.Seeking Alpha • Jun 24
Immunocore: KIMMTRAK Is Becoming A Cash Engine For A Much Larger TCR Platform
Summary Immunocore has transitioned from a rare-disease oncology company to a self-funded platform company with a validated commercial engine. KIMMTRAK's strong global sales, five-year survival data, and operating leverage underpin IMCR's ability to fund a broad pipeline without dilutive equity. Upcoming catalysts include pivotal readouts for tebentafusp and brenetafusp in melanoma, PRAME franchise expansion, and initial data in oncology, infectious disease, and autoimmune programs. IMCR trades at a 29% EV/Sales discount to sector median, with robust liquidity and multiple near-term clinical milestones supporting a favorable risk/reward profile. Read the full article on Seeking AlphaAnalyse-artikel • Jun 18
Immunocore Holdings (IMCR) Stock Could Be 57.1% Undervalued After Annual Results
Immunocore Holdings (IMCR) continues to attract attention after reporting annual revenue of US$412.8 million and a net loss of US$27.6 million, which puts its current US$1.45b market value into sharper focus for investors. See our latest analysis for Immunocore Holdings. At a share price of US$28.59, Immunocore Holdings has seen its share price return decline 15.36% year to date, while the 1 year total shareholder return is down 9.81%. This points to cooling momentum after several years of...Narratiefupdate • Jun 06
IMCR: Future Upside Will Rely On High Risk Oncology Pipeline Progress
Narrative Update on Immunocore Holdings Analysts have reduced their price target for Immunocore Holdings to $33, down from $48. They cite a moderate total addressable market for Kimmtrak in uveal melanoma, expectations that sales are nearing peak, and a view that further upside depends on higher risk pipeline progress.Narratiefupdate • May 19
IMCR: Future Upside Will Depend On Risky Oncology Pipeline Execution
Analysts now set Immunocore Holdings' fair value at $34, up $1 from $33. This reflects adjustments to assumptions around discount rate, revenue growth, profit margin and future P/E after recent Street research highlighted a more cautious view on upside without clearer pipeline progress.Narratiefupdate • Apr 25
IMCR: Pipeline Upside Will Rely On Higher Risk Oncology Programs
Analysts cut their price target on Immunocore Holdings to $33 from $48, noting that Kimmtrak provides an established revenue base in uveal melanoma. They indicated that the investment case now depends more on what they view as higher risk pipeline outcomes.Narratiefupdate • Apr 08
IMCR: Pipeline Risk And Sector Rotation Will Shape Balanced 2026 Outlook
Analysts have reset their average price target on Immunocore to $33. Some frame this move as a sign that Kimmtrak's uveal melanoma revenue potential is closer to peak, with future upside hinging more on higher risk pipeline assets, while others still see room for value in the broader small to mid cap biotech group.Narratiefupdate • Mar 24
IMCR: Sector Rotation And Pipeline Risk Will Shape Balanced 2026 Outlook
Narrative Update The analyst fair value estimate for Immunocore Holdings has shifted from $38 to $33. This change reflects mixed Street views, with some analysts highlighting Kimmtrak's moderate market and maturing sales, while others point to broader biotech sentiment and pipeline potential as key factors for future returns.Narratiefupdate • Mar 10
IMCR: Sector Rotation And Capital Production Shift Will Shape Bullish 2026 Outlook
Analysts have nudged their fair value estimate for Immunocore Holdings up from $37.00 to $38.00, citing higher Street price targets from $40 to $55. These targets reflect growing confidence in small to mid cap biotech as some companies are seen as shifting from capital consumers to capital producers and benefiting from improving sector sentiment.Narratiefupdate • Feb 24
IMCR: Bullish View Will Center On 2026 Capital Producer Transition
Analysts have nudged their average price target on Immunocore higher, with recent moves such as a lift to $40 and an upgrade anchored by a new $55 target. These changes support a small upward adjustment in our modeled fair value to $66.57, alongside slightly higher discount rate and P/E assumptions.Narratiefupdate • Feb 08
IMCR: Sector Rotation And Pipeline Execution Will Shape Bullish 2026 Outlook
Narrative Update on Immunocore Holdings Analysts have lifted their average price target for Immunocore to a range anchored by the recent US$40 and US$55 targets. This reflects updated assumptions on discount rates, revenue growth, profit margins, and future P/E multiples as they factor in improving sentiment toward small to mid cap biotech names.Narratiefupdate • Jan 24
IMCR: Balanced Outlook As Hepatitis B Data And Sector Rotation Shape 2026
Analysts have lifted their price target framework for Immunocore Holdings from about $24.93 to $37.00, reflecting recent Street research in which firms increased targets to as high as $55 and highlighted improving biotech fundamentals along with shifting investor attention toward small to mid cap commercial names. Analyst Commentary Recent Street research on Immunocore Holdings clusters around a common theme, with several firms linking their updated views to a broader shift in attention toward small to mid cap commercial biotech names.Narratiefupdate • Jan 10
IMCR: Bullish View Will Center On Advancing HBV TCR Bispecific Program
Narrative Update Analysts have lifted their blended price target for Immunocore, with recent moves such as a Morgan Stanley increase to $40 and a UBS move to $55 contributing to a higher implied fair value of about $66.36, based on updated assumptions for growth, margins and a higher future P/E multiple. Analyst Commentary Recent Street research around Immunocore centers on shifting views of small to mid cap biotech, updated price targets, and how investors might think about the balance between potential upside and execution risk.Analyse-artikel • Aug 02
Immunocore Holdings (NASDAQ:IMCR) Has Debt But No Earnings; Should You Worry?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analyse-artikel • Jun 10
Immunocore Holdings plc's (NASDAQ:IMCR) Price Is Right But Growth Is Lacking After Shares Rocket 27%
Immunocore Holdings plc ( NASDAQ:IMCR ) shareholders have had their patience rewarded with a 27% share price jump in...Seeking Alpha • Apr 27
Immunocore Holdings: A Name On My Watch List
Summary Immunocore Holdings' shares have fallen over 60% since February 2024 due to lack of catalysts and competition for its main product, Kimmtrak. Kimmtrak, approved for metastatic uveal melanoma, faces market saturation and competition, but label expansion could significantly increase its market potential. Immunocore's pipeline includes promising early-stage oncology and infectious disease programs, but pivotal data for key trials won't be available until 2H26 or later. An analysis around Immuncore Holdings follows in the paragraphs below. Read the full article on Seeking AlphaAnalyse-artikel • Apr 26
Improved Revenues Required Before Immunocore Holdings plc (NASDAQ:IMCR) Shares Find Their Feet
Immunocore Holdings plc's ( NASDAQ:IMCR ) price-to-sales (or "P/S") ratio of 4.9x might make it look like a buy right...
Nieuw narratief • Mar 23
AI Tools And Global Expansion Will Broaden KIMMTRAK's Market Reach
Expansion into less dense U.S. markets and international launches are key to driving revenue growth for Immunocore's KIMMTRAK.Analyse-artikel • Mar 04
Is Immunocore Holdings (NASDAQ:IMCR) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Feb 27
Immunocore: A Commercial Biotech Nearing Its Pivotal Break-Even Point
Summary Immunocore Holdings focuses on immunotherapy for oncology, with tebentafusp approved for metastatic uveal melanoma and brenetafusp in advanced trials. IMCR's strong balance sheet, with over $800 million in liquid assets, positions them well for future R&D or even a potential acquisition. Growth of tebentafusp sales has slowed, increasing reliance on new projects like brenetafusp, which carries inherent biotech industry risks. IMCR's financials show increased product revenue and net income, with substantial cash reserves to support ongoing and future developments. Read the full article on Seeking AlphaAnalyse-artikel • Jan 08
There Is A Reason Immunocore Holdings plc's (NASDAQ:IMCR) Price Is Undemanding
Immunocore Holdings plc's ( NASDAQ:IMCR ) price-to-sales (or "P/S") ratio of 5.2x might make it look like a strong buy...Seeking Alpha • Dec 10
Immunocore Is Adequately Valued, But Its Prospects Are Uncertain
Summary Immunocore's KIMMTRAK, targeting metastatic uveal melanoma, is FDA-approved and has shown significant clinical efficacy, with potential label expansions in cutaneous and adjuvant uveal melanoma. The company's ImmTAX platform develops TCR-based bispecific molecules, with ongoing trials for Tebentafusp and Brenetafusp in various cancers, showing promising early results. Financially, Immunocore has a strong cash position and stable revenue growth, but concerns remain about the pipeline's strength and clarity. Despite recent stock declines and cautious market sentiment, future trial successes could make current prices attractive for conservative investors. Read the full article on Seeking AlphaAnalyse-artikel • Oct 24
Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyse-artikel • Sep 19
Immunocore Holdings plc's (NASDAQ:IMCR) Business And Shares Still Trailing The Industry
Immunocore Holdings plc's ( NASDAQ:IMCR ) price-to-sales (or "P/S") ratio of 6.1x might make it look like a buy right...Seeking Alpha • Aug 12
Immunocore Holdings: KIMMTRAK Success, Diverse Pipeline, And Potential Big Pharma Appeal
Summary Immunocore Holdings is a biotech company with a promising revenue trajectory in 2024, driven by its leading product, KIMMTRAK. IMCR has a diverse pipeline with potential value drivers like IMC-F106C for cutaneous melanoma and IMC-M113V for HIV. The main risks stem from the Company's heavy reliance on KIMMTRAK and potential clinical trial failures for other pipeline drugs, such as IMC-F106C and IMC-M113V. I also believe IMCR could be a viable takeover target, given its diverse IP, growing revenues, and strong financials, which could potentially attract big pharma. Despite premium valuation risks, Immunocore's financials are robust, making it a "buy" for long-term investors familiar with biotech risks. Read the full article on Seeking AlphaAnalyse-artikel • Jul 24
Is Immunocore Holdings plc (NASDAQ:IMCR) Trading At A 33% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Immunocore Holdings fair value estimate is US$58.75 Immunocore...Analyse-artikel • Jun 16
Immunocore Holdings plc's (NASDAQ:IMCR) 28% Dip In Price Shows Sentiment Is Matching Revenues
To the annoyance of some shareholders, Immunocore Holdings plc ( NASDAQ:IMCR ) shares are down a considerable 28% in...Analyse-artikel • May 11
Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyse-artikel • May 11
Immunocore Holdings plc (NASDAQ:IMCR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Immunocore Holdings plc ( NASDAQ:IMCR ) shareholders are probably feeling a little disappointed, since its shares fell...Analyse-artikel • Apr 05
Are Investors Undervaluing Immunocore Holdings plc (NASDAQ:IMCR) By 25%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Immunocore Holdings fair value estimate is US$83.30 Immunocore...Analyse-artikel • Jan 22
Here's Why Immunocore Holdings (NASDAQ:IMCR) Can Manage Its Debt Despite Losing Money
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Seeking Alpha • Jan 21
Immunocore Holdings: Vulnerable To Profit Taking After Big Rally
Summary Immunocore Holdings plc is a commercial-stage biotechnology company focused on developing immunotherapies for cancer, infectious, and autoimmune diseases. The company's stock is up around 80% since late October and now is solidly in mid-cap territory. The stock has gotten shout outs from Barron's and Robert W. Baird to start the new year. Are further gains ahead in 2024 for Immunocore shareholders? An analysis follows in the paragraphs below. Read the full article on Seeking AlphaRendement voor aandeelhouders
| IMCR | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | -9.8% | -5.3% | -1.0% |
| 1Y | -7.5% | 37.0% | 14.1% |
Rendement versus industrie: IMCR presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 37 % opleverde.
Rendement versus markt: IMCR presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 14.1 % opleverde.
Prijsvolatiliteit
| IMCR volatility | |
|---|---|
| IMCR Average Weekly Movement | 4.7% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stabiele aandelenkoers: IMCR heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 5% ) van IMCR is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1999 | 524 | Bahija Jallal | www.immunocore.com |
Immunocore Holdings plc houdt zich, samen met haar dochterondernemingen, bezig met de ontwikkeling en commercialisering van immunomodulerende geneesmiddelen voor patiënten met kanker, infectieziekten en auto-immuunziekten in de Verenigde Staten, Europa en internationaal. Het bedrijf biedt KIMMTRAK aan voor de behandeling van niet-resectabel of metastatisch uveaal melanoom. Het ontwikkelt ook oncologieprogramma's, waaronder tebentafusp dat zich in Fase 3 van het klinisch onderzoek bevindt voor de behandeling van gevorderd cutaan melanoom en adjuvant uveaal melanoom; brenetafusp dat zich in Fase 3 van het klinisch onderzoek bevindt voor de behandeling van eerstelijns gevorderd cutaan melanoom en in Fase 1/2 van het klinisch onderzoek voor de behandeling van verschillende tumortypes; IMC-R117C, in Fase 1/2 van het klinisch onderzoek voor de behandeling van vergevorderde vaste tumoren, zoals colorectale kanker; en IMC-P115C, in Fase 1 van het klinisch onderzoek voor patiënten met tumoren die PRAME tot expressie brengen.
Immunocore Holdings plc Samenvatting
| IMCR fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$1.68b |
| Inkomsten(TTM) | -US$18.07m |
| Inkomsten(TTM) | US$430.78m |
3.9x
P/S-verhouding-92.9x
Koers/WinstverhoudingIs IMCR overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| IMCR resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$430.78m |
| Kosten van inkomsten | US$289.19m |
| Brutowinst | US$141.59m |
| Overige uitgaven | US$159.66m |
| Inkomsten | -US$18.07m |
Laatst gerapporteerde inkomsten
Jun 30, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -0.35 |
| Brutomarge | 32.87% |
| Nettowinstmarge | -4.20% |
| Schuld/Eigen Vermogen Verhouding | 93.9% |
Hoe presteerde IMCR op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/09/12 08:26 |
| Aandelenkoers aan het einde van de dag | 2026/09/11 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Immunocore Holdings plc wordt gevolgd door 25 analisten. 14 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Jack Allen | Baird |
| William Maughan | Canaccord Genuity |
| Eric Schmidt | Cantor Fitzgerald & Co. |